Durable disease control in unresectable hepatocellular carcinoma with atezolizumab plus half-dose bevacizumab: pathological complete response of peritoneal metastasis
{{output}}
Background: Atezolizumab plus bevacizumab (ATZ + BV) is the standard first-line therapy for unresectable hepatocellular carcinoma (HCC). However, long-term treatment is frequently limited by adverse events such as proteinuria and... ...
